SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
The Anopheles stephensi mosquito is a vector of malaria. (Photo: CDC/ Dr. William Collins)
With Possible 'Major Public Health Impact,' Malaria Vaccine Advances
Research publication on effectiveness of new vaccine follows announcement by pharmaceutical corporation GlaxoSmithKline that it is applying for first ever approval of anti-malaria vaccine on EU markets.
Jul 30, 2014
An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.
The publication follows GSK's announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.
Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at "11 African Sites" where Malaria is prevalent.
Over the course of 18 months, the researchers found that the vaccine "averted an average of 829 and 449 cases of clinical malaria per 1,000 children and infants vaccinated, respectively."
According to the study's authors, the findings show significant effectiveness and suggest that the vaccine "could have a major public health impact in sub-Saharan Africa."
Malaria disproportionately affects poor and rural communities in the global south, hitting sub-Saharan Africa the hardest. Despite being preventable and curable if addressed promptly, the disease is a top cause of death and illness throughout the developing world, killing approximately 1.2 million people a year, the vast majority of them children.
Join Us: News for people demanding a better world
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Sarah Lazare
Sarah Lazare was a staff writer for Common Dreams from 2013-2016. She is currently web editor and reporter for In These Times.
An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.
The publication follows GSK's announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.
Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at "11 African Sites" where Malaria is prevalent.
Over the course of 18 months, the researchers found that the vaccine "averted an average of 829 and 449 cases of clinical malaria per 1,000 children and infants vaccinated, respectively."
According to the study's authors, the findings show significant effectiveness and suggest that the vaccine "could have a major public health impact in sub-Saharan Africa."
Malaria disproportionately affects poor and rural communities in the global south, hitting sub-Saharan Africa the hardest. Despite being preventable and curable if addressed promptly, the disease is a top cause of death and illness throughout the developing world, killing approximately 1.2 million people a year, the vast majority of them children.
Sarah Lazare
Sarah Lazare was a staff writer for Common Dreams from 2013-2016. She is currently web editor and reporter for In These Times.
An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.
The publication follows GSK's announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.
Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at "11 African Sites" where Malaria is prevalent.
Over the course of 18 months, the researchers found that the vaccine "averted an average of 829 and 449 cases of clinical malaria per 1,000 children and infants vaccinated, respectively."
According to the study's authors, the findings show significant effectiveness and suggest that the vaccine "could have a major public health impact in sub-Saharan Africa."
Malaria disproportionately affects poor and rural communities in the global south, hitting sub-Saharan Africa the hardest. Despite being preventable and curable if addressed promptly, the disease is a top cause of death and illness throughout the developing world, killing approximately 1.2 million people a year, the vast majority of them children.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.